Skip to Content
Merck
All Photos(1)

Key Documents

Y0001434

Montelukast sodium

European Pharmacopoeia (EP) Reference Standard

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C35H35ClNO3S·Na
CAS Number:
151767-02-1
Molecular Weight:
608.17
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

montelukast

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

InChI

1S/C35H36ClNO3S.Na/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29;/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39);/q;+1/p-1/b15-10+;/t32-;/m1./s1

InChI key

LBFBRXGCXUHRJY-HKHDRNBDSA-M

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Montelukast sodium EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

Y0001433

Montelukast racemate, European Pharmacopoeia (EP) Reference Standard

Y0001435

Montelukast for peak identification, European Pharmacopoeia (EP) Reference Standard

Y0001436

Montelukast dicyclohexylamine, European Pharmacopoeia (EP) Reference Standard

1446859

Montelukast sodium, United States Pharmacopeia (USP) Reference Standard

1446848

Montelukast racemate, United States Pharmacopeia (USP) Reference Standard

1446815

Montelukast dicyclohexylamine, United States Pharmacopeia (USP) Reference Standard

1446837

Montelukast for peak identification, United States Pharmacopeia (USP) Reference Standard

BP1147

Montelukast dicyclohexylamine, British Pharmacopoeia (BP) Reference Standard

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Nathan Rabinovitch et al.
The Journal of allergy and clinical immunology, 133(2), 350-356 (2013-10-03)
Predictors of improvement in asthma control and lung function to step 3 therapy in children with persistent asthma have not been identified despite reported heterogeneity in responsiveness. We sought to evaluate potential predictors of asthma control and lung function responsiveness
Timothy S Chang et al.
The Journal of allergy and clinical immunology, 133(2), 363-369 (2013-10-22)
Childhood asthma clusters, or subclasses, have been developed by computational methods without evaluation of clinical utility. To replicate and determine whether childhood asthma clusters previously identified computationally in the Severe Asthma Research Program (SARP) are associated with treatment responses in
Yves Pacheco et al.
The Journal of asthma : official journal of the Association for the Care of Asthma, 51(1), 1-17 (2013-07-10)
Rhinitis and other specific triggers or co-morbidities (tobacco exposure, excess weight, aspirin sensitivity or heredity factors) are frequently associated with uncontrolled asthma. Asthma associated with these exacerbating factors appears to be related to an increase in leukotriene-mediated inflammation. We reviewed
Stefano Fogli et al.
Pharmacological research, 76, 149-156 (2013-08-21)
Microparticles (MPs) are membrane fragments that may play a role in the pathogenesis of chronic respiratory diseases. We aimed to investigate whether human monocytes/macrophage-derived MPs could induce a pro-inflammatory phenotype in human bronchial smooth muscle cells (BSMC) and the effect
Genyo Ikeda et al.
American journal of respiratory cell and molecular biology, 50(1), 18-29 (2013-08-14)
The incidence of overlapping bronchial asthma and chronic obstructive pulmonary disease has increased in recent years. Cysteinyl leukotrienes (CysLTs) play an important role in asthma, and the type 1 CysLT receptor (CysLT1R) is expressed by many inflammatory cells. We evaluated
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service